Drug
Vepdegestrant clinical trials
Also written ARV-471 and PF-07850327.
- studies test it
- 20
- open now
- 2
- in phase 3
- 2
- first study started
- 2010
Keep track of what changes. Save the vepdegestrant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- ARV-471
- 12
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2023 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 10 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 1
Pfizer (17) · Arvinas Estrogen Receptor, Inc. (1) · Arvinas Inc. (1) · QuantumLeap Healthcare Collaborative (1)
Often tested with
Tested in the same studies.
Abemaciclib (2) · Atirmociclib (1) · Ribociclib (1) · Samuraciclib (1) · Palbociclib (1) · Midazolam (1) · Itraconazole (1) · Dabigatran (1)
Studies
Open first, then newest update. How each study uses vepdegestrant is read from its arms, and is right about nine times in ten.
Testing it · 20
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as ARV-471
- A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionRecruitingPhase 1PfizerNCT07231991Written as vepdegestrant
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)CompletedPhase 1/2PfizerNCT06125522Written as vepdegestrant
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingPhase 1/2PfizerNCT06206837Written as vepdegestrant
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedPhase 1/2Arvinas Estrogen Receptor, Inc.NCT04072952Written as Vepdegestrant
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingPhase 1/2PfizerNCT05548127Written as ARV-471
- A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy AdultsCompletedPhase 1PfizerNCT05930925Written as [phenyl-14C]ARV-471
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingPhase 3PfizerNCT05654623Written as ARV-471
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)Active, not recruitingPhase 1/2PfizerNCT05573555Written as ARV-471
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive, not recruitingPhase 3PfizerNCT05909397Written as Vepdegestrant (ARV-471/PF-07850327)
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryCompletedPhase 2Arvinas Inc.NCT05549505Written as ARV-471
- A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy AdultsCompletedPhase 1PfizerNCT06911788Written as Vepdegestrant (Reference)
- A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaCompletedPhase 1PfizerNCT05732428Written as ARV-471
- A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called MidazolamCompletedPhase 1PfizerNCT06256510Written as Vepdegestrant
- A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)Active, not recruitingPhase 1PfizerNCT05463952Written as vepdegestrant
- A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy AdultsCompletedPhase 1PfizerNCT05538312Written as vepdegestrant
- A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy AdultsCompletedPhase 1PfizerNCT05673889Written as ARV-471
- A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy AdultsCompletedPhase 1PfizerNCT05652660Written as ARV-471
- A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine VepdegestrantCompletedPhase 1PfizerNCT06275841Written as vepdegestrant
- A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy ParticipantsCompletedPhase 1PfizerNCT06005688Written as Vepdegestrant
Given in every arm · 1 — vepdegestrant is usual care beside what is tested
Codes
What other systems call vepdegestrant · ClinicalTrials.gg INT002220
- MeSH (NLM) C000732096vepdegestrantOne source NLM
- UNII (FDA) WC1U3R1YMIVEPDEGESTRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q123965022vepdegestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C165420VepdegestrantOne source FDA
- DrugBank DB19006One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732096 | vepdegestrant | One source NLM |
| UNII (FDA) | WC1U3R1YMI | VEPDEGESTRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123965022 | vepdegestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C165420 | Vepdegestrant | One source FDA |
| DrugBank | DB19006 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.